Meeting NewsVideo

VIDEO: IBD notes from UEGW include treat-to-target, JAK-1 inhibitors

ORLANDO — In this exclusive video from Advances in IBD 2017, Edward V. Loftus, MD, of the Mayo Clinic, recaps important inflammatory bowel disease research shared recently at UEG Week in Barcelona.

First, he discussed the results of the CALM study, which showed a treat-to-target strategy using “tight control” of inflammatory biomarkers improved outcomes in patients with Crohn’s disease being treated with Humira. You can read more about that study here.

“Also, a cost-effectiveness analysis suggested that employing a treat-to-target strategy would be within the realm of cost-effectiveness,” Loftus told Healio Gastroenterology and Liver Disease.

Other important abstracts reported data on new investigational agents including oral JAK-1 inhibitors like filgotinib and upadacitinib.

“We saw a sub-analysis of the FITZROY trial that showed that regardless of your disease duration or your disease extent, filgotinib was significantly better than placebo in achieving the primary and secondary clinical endpoints,” he said. “We also saw a reprise of the primary upadacitinib results ... showing that several different doses ... were significantly better than placebo at achieving endoscopic endpoints as well as relevant clinical endpoints.”

Disclosures: Loftus reports financial relationships with AbbVie, Allergan, Amgen, Celgene, Celltrion, CVS Caremark, Eli Lilly, Genentech, Gilead, Janssen, MedImmune, Mesoblast, Pfizer, Robarts Clinical Trials, Salix, Seres, Takeda and UCB.

ORLANDO — In this exclusive video from Advances in IBD 2017, Edward V. Loftus, MD, of the Mayo Clinic, recaps important inflammatory bowel disease research shared recently at UEG Week in Barcelona.

First, he discussed the results of the CALM study, which showed a treat-to-target strategy using “tight control” of inflammatory biomarkers improved outcomes in patients with Crohn’s disease being treated with Humira. You can read more about that study here.

“Also, a cost-effectiveness analysis suggested that employing a treat-to-target strategy would be within the realm of cost-effectiveness,” Loftus told Healio Gastroenterology and Liver Disease.

Other important abstracts reported data on new investigational agents including oral JAK-1 inhibitors like filgotinib and upadacitinib.

“We saw a sub-analysis of the FITZROY trial that showed that regardless of your disease duration or your disease extent, filgotinib was significantly better than placebo in achieving the primary and secondary clinical endpoints,” he said. “We also saw a reprise of the primary upadacitinib results ... showing that several different doses ... were significantly better than placebo at achieving endoscopic endpoints as well as relevant clinical endpoints.”

Disclosures: Loftus reports financial relationships with AbbVie, Allergan, Amgen, Celgene, Celltrion, CVS Caremark, Eli Lilly, Genentech, Gilead, Janssen, MedImmune, Mesoblast, Pfizer, Robarts Clinical Trials, Salix, Seres, Takeda and UCB.

    See more from Advances in IBD